Please ensure Javascript is enabled for purposes of website accessibility

E.I. du Pont de Nemours & Co. (DD)

E.I. du Pont de Nemours & Co. (DD – yield 3.80%)—DuPont, the large chemical company, has long frequented the ranks of high-dividend stocks. Its current yield [is almost] 4% per year ($1.64 annual dividend per share). The company’s earnings are very sensitive to the health of the world’s...

E.I. du Pont de Nemours & Co. (DD – yield 3.80%)—DuPont, the large chemical company, has long frequented the ranks of high-dividend stocks. Its current yield [is almost] 4% per year ($1.64 annual dividend per share). The company’s earnings are very sensitive to the health of the world’s economies. Current S&P earnings estimates for 2011 are double what DuPont earned in 2009, although that may prove to be too optimistic. Even so, earnings are far higher now than they were in 2002-2005, when the share price was similar to where DuPont trades now.

“Downside risk in the event that the market decline extends further would be $34/share. However, given the share price history in the chart, the current price (area of $41/share) appears to be a reasonable area in which to open covered call positions. The stock is attractive for that because its options are expensive. The third quarter earnings report is scheduled for Tuesday, October 25. That makes it likely that November options will be pricey after the expiration of October options. Recommendation: Buy DuPont at $41/share or lower.”

Dr. Marvin Appel and Gerald Appel, Systems & Forecasts, 10/6/11

Marvin Appel, Ph.D., was originally trained as an anesthesiologist at Harvard University Medical School and John Hopkins Hospital, concurrently earning a PhD in Biomedical Engineering from Harvard University where he did his undergraduate work as well. In 1996, he joined his father, Gerald Appel, in organizing Appel Asset Management Corporation. He is the editor of Systems & Forecasts, which receives very high marks for its performance relative to buy and hold bond and stock investment strategies, for its emphasis on risk-control, and for the performance of its investment strategies. Dr. Appel is the author and co-author of three books, “Investing with Exchange-Traded Funds Made Easy,” (two editions), and “Beating the Market, Three Months at a Time.” Dr. Appel is currently working on a fourth book, “Higher Returns From Safe Investments.” Dr. Appel’s market insights have been featured on CNNfn, CNBC, CBS MarketWatch and Forbes.com.